As a result, individuals taking GLP-1 receptor agonists often experience substantial weight loss
Infections, tissue necrosis, nerve injury, uneven fat loss, or product inconsistency are rare but documented risks requiring careful practice
doi: 10.1016/j.survophthal.2021.08.011 95 SantosARRibeiroLBandelloFLattanzioREganCFrydkjaer-OlsenUet al
As Dermatologist Katherine Armour, a Melbourne-based skin expert, says, "There is often a change in the appearance of many of their moles, such that it can be difficult to detect melanomas or sometimes, clinically, for us to exclude melanoma." Melanotan is classified as an unapproved product by Australias Therapeutic Goods Administration (TGA)
The generational picture Age differences in attitudes towards oral GLP-1s Attitudes towards oral GLP-1 treatments vary significantly by age